Haleon (HLN) Stock Forecast & Price Target

$9.69 -0.01 (-0.10%)

(As of 12/20/2024 04:33 PM ET)

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 1 has given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$10.95
13.00% Upside

According to the 6 analysts' twelve-month price targets for Haleon, the average price target is $10.95. The highest price target for HLN is $10.95, while the lowest price target for HLN is $10.95. The average price target represents a forecasted upside of 13.00% from the current price of $9.69.

Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

HLN Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.95	$10.95	$10.95	N/A
Forecasted Upside	13.00% Upside	14.60% Upside	4.09% Upside	N/A
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Haleon Stock vs. The Competition

Type	Haleon	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.00% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent HLN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	UBS Group 4 of 5 stars	G. Delmas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/20/2024	Morgan Stanley 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$9.90 ➝ $10.95	+4.78%
8/6/2024	Berenberg Bank 2 of 5 stars	B. Davies Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Nicolai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
3/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
8/8/2023	Investec Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
5/24/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
4/4/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
1/31/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 360 ➝ GBX 364

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:34 PM ET.

Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

Here are some ways that investors could benefit from investing in Haleon plc:

Haleon plc has received multiple upgrades from investment analysts, including a "strong-buy" rating from UBS Group, indicating strong confidence in the company's future performance.
The stock currently trades at $9.39, which is above its 12-month low of $7.89, suggesting a potential for growth as it approaches its 12-month high of $10.80.
With a market capitalization of $42.51 billion, Haleon plc is positioned as a significant player in the consumer healthcare market, which can provide stability and growth opportunities.
The company has a diverse product portfolio, including well-known brands like Sensodyne and Voltaren, which can help mitigate risks associated with market fluctuations.
Recent reports indicate a consensus rating of "Buy" with an average target price of $10.95, suggesting that analysts expect the stock to appreciate in value.

Haleon
Bear Case

Investors should be bearish about investing in Haleon plc for these reasons:

The downgrade from Goldman Sachs from a "buy" to a "neutral" rating may signal potential concerns about the company's short-term performance.
Haleon plc has a relatively high price-to-earnings (P/E) ratio of 27.34, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
The company's quick ratio of 0.58 suggests that it may struggle to meet short-term liabilities, which could be a red flag for investors concerned about liquidity.
Despite a strong product lineup, the consumer healthcare market is highly competitive, and any loss of market share could negatively impact Haleon's financial performance.
The stock's beta of 0.30 indicates lower volatility compared to the market, which may limit potential gains for investors looking for high-risk, high-reward opportunities.

HLN Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $10.95, with a high forecast of $10.95 and a low forecast of $10.95.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There is currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLN shares.
: According to analysts, Haleon's stock has a predicted upside of 13.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Haleon's stock had 1 upgrade by analysts.
: Haleon has been rated by research analysts at UBS Group in the past 90 days.
: Analysts like Haleon more than other "medical" companies. The consensus rating for Haleon is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

This page (NYSE:HLN) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haleon (HLN) Stock Forecast & Price Target